Positive Oncology News Lifts OncoMed - Analyst Blog

By
A A A

Shares of OncoMed Pharmaceuticals, Inc. ( OMED ) were positively impacted with the company presenting encouraging data on its oncology candidates, demcizumab and OMP-59R5, at the 2014 Gastrointestinal Cancers Symposium.

Initial data on demcizumab from an ongoing phase Ib study revealed that the candidate in combination with Celgene Corporation 's ( CELG ) Abraxane and Eli Lilly and Company 's ( LLY ) Gemzar (gemcitabine) was well tolerated as a first-line therapy in patients suffering from stage IV pancreatic cancer. Data also revealed that 50% of patients treated with the above combination showed partial responses, according to the response evaluation criteria in solid tumors (RECIST). Moreover, around 33% of patients had stable disease with an 83% clinical benefit rate.

Encouraged by the impressive results, OncoMed, which went public only in July last year, intends to evaluate the candidate as a first-line therapy in the advanced pancreatic cancer indication in the latter half of 2014. We note that demcizumab is part of OncoMed's oncology deal with Celgene inked late last year. The deal pertains to the joint development and commercialization of up to six anti-cancer stem cell candidates from OncoMed's biologics pipeline.


OncoMed also presented encouraging initial data from the phase Ib portion of its ongoing ALPINE (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety) study on another of its pipeline candidate OMP-59R5. The study is also evaluating OMP-59R5 in combination with Gemzar and Abraxane as a first-line therapy in patients with advanced pancreatic cancer. OncoMed intends to evaluate the candidate in a phase II portion of the ALPINE study in the second quarter of 2014.  We believe investor focus will remain on updates pertaining to these candidates.

OncoMed, a biopharmaceutical company, carries a Zacks Rank #2 (Buy). A better-ranked stock in the biopharma space includes Actelion Ltd. ( ALIOF ) which carries a Zacks Rank #1 (Strong Buy).



ACTELION LTD (ALIOF): Get Free Report

CELGENE CORP (CELG): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

ONCOMED PHARMA (OMED): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , CELG , LLY , OMED

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,974,386
  • $17.98 ▲ 0.28%
20,763,901
  • $91.29 ▲ 2.06%
19,110,793
  • $7.26 ▼ 1.22%
18,528,869
    $8.33 unch
18,014,920
  • $4.19 ▼ 1.18%
16,448,919
  • $25.83 ▼ 0.19%
14,748,190
  • $7.60 ▼ 1.43%
14,144,383
  • $112.01 ▼ 0.47%
As of 12/24/2014, 02:12 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com